DOCSLIB.ORG

Predicting Chemotherapy-Induced Febrile Neutropenia Outcomes in Adult Cancer Patients: an Evidence-Based Prognostic Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Predicting Chemotherapy-Induced Febrile Neutropenia Outcomes in Adult Cancer Patients: an Evidence-Based Prognostic Model Predicting Chemotherapy-Induced Febrile Neutropenia Outcomes in Adult Cancer Patients: An Evidence-Based Prognostic Model Yee Mei, Lee Cert Nursing (S’pore), RN, Adv. Dip. (Oncology) in Nursing (S’pore), Bsc of Nursing (Monash), Master of Nursing (S’pore) Thesis submitted for the Doctor of Philosophy School of Translational Health Science The University of Adelaide Adelaide, South Australia Australia November 2013 Table of Contents TABLE OF CONTENTS -------------------------------------------------------------------- II LIST OF TABLES ------------------------------------------------------------------------ VII LIST OF FIGURES ---------------------------------------------------------------------- VIII LIST OF ABBREVIATIONS --------------------------------------------------------------- XI ABSTRACT ----------------------------------------------------------------------------- XII DECLARATION ----------------------------------------------------------------------- XIIII ACKNOWLEDGEMENTS-- ------------------------------------------------------------ IXV PUBLICATIONS ------------------------------------------------------------------------ XV 1 INTRODUCTION TO THE THESIS ---------------------------------------------------- 15 1.1 CLINICAL CONTEXT -------------------------------------------------------------------------------- 15 1.2 CLINICAL IMPACT OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA -------------------- 16 1.3 ECONOMIC IMPLICATIONS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA ---------- 18 1.4 EVOLVING PRACTICE IN THE MANAGEMENT OF FEBRILE NEUTROPENIA ---------------------- 18 1.5 PROGNOSTIC FACTORS AND PROGNOSTIC MODELS ------------------------------------------ 21 1.6 PROGNOSTIC FACTORS AND MODELS FOR RISK STRATIFICATION OF FEBRILE NEUTROPENIA PATIENTS -------------------------------------------------------------------------------------------- 22 1.7 CURRENT STATE OF PROGNOSTIC FACTORS AND MODELS FOR RISK STRATIFICATION OF FEBRILE NEUTROPENIA PATIENTS ------------------------------------------------------------------ 23 1.8 OPTIMAL PROGNOSTIC MODEL FOR RISK STRATIFICATION OF FEBRILE NEUTROPENIA PATIENTS ------------------------------------------------------------------------------------------------------ 25 1.9 SIGNIFICANCE OF THE RESEARCH ---------------------------------------------------------------- 25 1.10 STRUCTURE OF THE THESIS ------------------------------------------------------------------------- 26 2 BACKGROUND -------------------------------------------------------------------- 27 2.1 INTRODUCTION TO THE CHAPTER ----------------------------------------------------------------- 27 2.2 NEUTROPHILS AND THE BODY IMMUNE SYSTEM ------------------------------------------------- 27 2.3 GRADES OF NEUTROPENIA ----------------------------------------------------------------------- 29 2.4 CHEMOTHERAPY-INDUCED NEUTROPENIA ------------------------------------------------------ 30 2.5 CHALLENGES IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA 32 2.6 CHEMOTHERAPY-INDUCED NEUTROPENIA AND FEBRILE NEUTROPENIA – RISK FACTORS AND PREVENTIVE MEASURES ---------------------------------------------------------------------------- 34 2.6.1 Use of colony-stimulating factors in patients with neutropenia ---- 35 2.6.2 Use of antimicrobial prophylaxis in patients with neutropenia ----- 37 2.7 FACTORS PREDICTIVE OF FEBRILE NEUTROPENIA OUTCOMES ---------------------------------- 39 2.7.1 Patient-related factors ----------------------------------------------------------- 39 2.7.2 Disease-related factors ---------------------------------------------------------- 43 2.7.3 Treatment–related factors ------------------------------------------------------ 45 2.7.4 Febrile episode-related factors ----------------------------------------------- 47 2.7.5 Diagnostic / Laboratory markers --------------------------------------------- 53 ii 2.8 SUMMARY OF PROGNOSTIC FACTORS FOR THE RISK STRATIFICATION OF PATIENTS WITH FEBRILE NEUTROPENIA ----------------------------------------------------------------------------- 58 2.9 PROGNOSTIC MODELS FOR RISK STRATIFICATION OF PATIENTS WITH FEBRILE NEUTROPENIA 59 2.9.1 Talcott model ----------------------------------------------------------------------- 60 2.9.2 MASCC risk-index score --------------------------------------------------------- 62 2.9.3 Risk model for patients with haematology malignancies ------------ 63 2.9.4 Summary of the prognostic models ----------------------------------------- 65 2.10 CURRENT STATE OF EVIDENCE -------------------------------------------------------------------- 65 3 SYSTEMATIC REVIEW OF PROGNOSTIC FACTORS FOR FEBRILE NEUTROPENIA OUTCOMES IN ADULT CANCER PATIENTS --------------------------------------- 67 3.1 INTRODUCTION TO THE CHAPTER ----------------------------------------------------------------- 67 3.2 EVIDENCE-BASED PRACTICE ---------------------------------------------------------------------- 67 3.3 BARRIERS OF EVIDENCE-BASED HEALTHCARE ADOPTION -------------------------------------- 69 3.4 THE JOANNA BRIGGS INSTITUTE MODEL OF EVIDENCE-BASED HEALTHCARE ---------------- 70 3.4.1 Framework of the Joanna Briggs Institute model ----------------------- 71 3.5 SYSTEMATIC REVIEW ------------------------------------------------------------------------------- 74 3.6 SCOPE OF REVIEW FOR FACTORS ASSOCIATED WITH FEBRILE NEUTROPENIA OUTCOMES -- 76 3.7 CHALLENGES ASSOCIATED WITH SYSTEMATIC REVIEW OF PROGNOSTIC FACTORS --------- 78 3.8 META-ANALYSIS OF INDIVIDUAL PATIENT DATA ------------------------------------------------- 80 3.9 SYSTEMATIC REVIEW PROTOCOL ----------------------------------------------------------------- 82 3.9.1 Statement of the review question ------------------------------------------- 82 3.9.2 Objectives of the review -------------------------------------------------------- 82 3.9.3 Review Questions: ----------------------------------------------------------------- 82 3.9.4 Inclusion criteria -------------------------------------------------------------------- 82 3.9.5 Search strategy -------------------------------------------------------------------- 87 3.9.6 Method of the review ------------------------------------------------------------ 89 3.9.7 Results of the systematic review ---------------------------------------------- 91 3.9.8 Review findings --------------------------------------------------------------------- 98 3.9.9 Patient-related factors --------------------------------------------------------- 100 3.9.10 Disease-related factors -------------------------------------------------------- 101 3.9.11 Treatment-related factors ---------------------------------------------------- 101 3.9.12 Febrile neutropenia episode-related factors --------------------------- 103 3.9.13 Laboratory markers ------------------------------------------------------------- 106 3.9.14 Factors summarised according to the odd ratios -------------------- 108 3.9.15 Summary of the review findings -------------------------------------------- 111 3.9.16 Discussion --------------------------------------------------------------------------- 112 3.9.17 Limitations of the Review ------------------------------------------------------ 121 3.9.18 Conclusions to the systematic review ------------------------------------ 123 3.9.19 Implications for practice ------------------------------------------------------ 123 3.9.20 Implications for research ------------------------------------------------------ 124 iii 4 PRIMARY STUDY TO ESTABLISH CANDIDATE FACTORS FOR THE PROGNOSIS OF FEBRILE NEUTROPENIA ----------------------------------------------------------- 126 4.1 INTRODUCTION TO THE CHAPTER --------------------------------------------------------------- 126 4.2 PROGNOSIS AND ITS UTILITY IN DECISION MAKING ------------------------------------------- 126 4.3 SINGLE VERSUS MULTIPLE PREDICTORS IN PROGNOSTICATION ------------------------------ 127 4.4 TYPES OF PROGNOSTIC STUDIES ---------------------------------------------------------------- 129 4.5 PROGNOSTIC FACTORS AND MODEL DEVELOPMENT ---------------------------------------- 131 4.6 QUALITY OF PROGNOSTIC STUDIES ------------------------------------------------------------- 132 4.6.1 Study design: prospective compared with retrospective designs --- ----------------------------------------------------------------------------------------- 133 4.6.2 Selection of candidate variables ------------------------------------------ 135 4.6.3 Choice of appropriate outcome measures ---------------------------- 136 4.6.4 Sample size and events in analysis – some limitations --------------- 137 4.6.5 Reporting of results -------------------------------------------------------------- 138 4.7 PRIMARY STUDY: DESIGN AND METHODS ---------------------------------------------------- 139 4.7.1 Justification for primary study ------------------------------------------------ 139 4.7.2 Purpose of the study ------------------------------------------------------------ 140 4.7.3 Study questions: ------------------------------------------------------------------ 140 4.7.4 Site of study ------------------------------------------------------------------------ 141 4.7.5 Study design ----------------------------------------------------------------------- 141 4.7.6 Sampling ---------------------------------------------------------------------------- 143 4.7.7 Study population ---------------------------------------------------------------- 144 4.7.8 Sample Size ------------------------------------------------------------------------ 144 4.7.9 Operational
Load more

Recommended publications
  • Dreaming in Patients with Temporal Lobe Epilepsy: a Focus on Bad Dreams and Nightmares Carmen Anderson Department of Psychology
    1 Dreaming in Patients with Temporal Lobe Epilepsy: A Focus on Bad Dreams and Nightmares Carmen Anderson Department of Psychology University of Cape Town 29th October 2012 Supervisor: Prof. Mark Solms Co-supervisor: Warren King Word count: 7055 Abstract: 164 Main body: 6891 2 Abstract Nightmares and bad dreams occur more frequently in patients with temporal lobe epilepsy (TLE) than in normal individuals. This quantitative pilot study explored the relationship between seizure activity and dreaming in patients with TLE, compared to the dreams, bad dreams and nightmares of a control population. Groups were categorized by epilepsy variables (TLE and non-TLE) and gender. Patients with temporal lobe epilepsy completed self-report questionnaires concerning their epilepsy and dreaming, and this data was compared to dreaming data from the control group using ANCOVAs. The results showed that females have significantly higher scores than males on several variables, including dreams per week, bad dream distress and nightmare distress. However, no significant main effects or interactions were found for the variables bad dream frequency and nightmare frequency, which contradicts the study’s hypotheses. It is possible that this lack of differences was due to TLE patients being on antiepileptic drugs, which whilst controlling seizures, may have suppressed or eliminated the effects of bad dreams and nightmares. Keywords: temporal lobe epilepsy, dreaming, bad dreams, nightmares, gender differences. 3 Dreaming in Patients with Temporal Lobe Epilepsy: A Focus on Bad Dreams and Nightmares Nightmares and bad dreams occur more frequently in patients with temporal lobe epilepsy (TLE) than in normal individuals and in patients with generalized seizures (Silvestri & Bromfield, 2004).
    [Show full text]
  • Anemias Supportive Module 4 "Essentials of Diagnosis, Treatment and Prevention of Major Hematologic Diseases"
    2016/2017 Spring Semester Anemias Supportive module 4 "Essentials of diagnosis, treatment and prevention of major hematologic diseases" LECTURE IN INTERNAL MEDICINE FOR IV COURSE STUDENTS M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko, N. Makienko V.N. Karazin National University Medical School’ Internal Medicine Dept. Plan of the lecture • Definition • Epidemiology • Etiology • Mechanisms • Adaptation to anemia • Classification • Clinical investigation • Diagnosis • Treatment • Prognosis • Prophylaxis • Abbreviations • Diagnostic guidelines http://anemiaofchronicdisease.com/wp-content/uploads/2012/08/anemia-of-chronic-disease1.jpg Definition Anemia is a disease and/or a clinical syndrome that consist in lowered ability of the blood to carry oxygen (hypoxia) due to decrease quantity and functional capacity and/or structural disturbances of red blood cells (RBCs) or decrease hemoglobin concentration or hematocrit in the blood A severe form of anemia, in which the hematocrit is below 10%, is called the hyperanemia WHO criteria is Hb < 13 g/dL in men and Hb < 12 g/dL in women (revised criteria for patient’s with malignancy Hb < 14 g/dL in men and Hb < 12g/dL in women) Epidemiology 1 https://www.k4health.org/sites/default/files/anemia-map_updated.png Epidemiology 2 http://img.medscape.com/fullsize/migrated/editorial/conferences/2006/4839/spivak.fig1.jpg Epidemiology 3 http://www.omicsonline.org/2161-1165/images/2161-1165-2-118-g001.gif Etiology 1 (basic forms) Basic forms • Blood loss • Deficient erythropoiesis • Excessive
    [Show full text]
  • Download Dr. Qureshi's CV
    Brief Synopsis Nazer H. Qureshi, M.D, D.Stat, M.Sc, DABNS, FAANS. Graduated from Medical School with top honors and first position in Anatomy and Histology in board examinations. Pursued surgical training in Europe including neurosurgery at the National Center for Neurosurgery affiliated with The Royal College of Surgeons of Ireland. In 1994 started as a junior faculty member at University of Dublin teaching medical students while pursuing his own research on “Interleukin-1 binding and expression in brain” towards Masters in Science. During that year also attained a Diploma in Statistics from University of Dublin. In summer of 1995 was a visiting fellow at University of Toronto working on use- dependent inhibitory depression in epilepsy models. In 1996 migrated to US and completed a research fellowship in gene therapy for brain tumors at Harvard Medical School/Massachusetts General Hospital. The work on gene therapy that included testing efficacy and toxicity of different viral vectors and & designing a novel method of gene delivery to human brain tumors culminated into a clinical trial. In 1999 completed a neurosurgery fellowship at University of Arizona. Completed 2 years of accredited General Surgery residency at Tuft’s University and Thomas Jefferson University followed by Neurosurgery Residency in June 2008 from University of Arkansas for Medical Sciences with “Prof. Iftikhar A. Raja Humanity in Medicine Award.” Diplomate American Board of Neurological Surgeons and Fellow of the American Board of Neurological Surgeons. Worked as an attending neurosurgeon at Baptist Hospital Medical Center in Little Rock the chief of brain and spine tumor service at Baptist Health Medical Center, North Little Rock.
    [Show full text]
  • Iron Deficiency Anemia (Ida) Recommendations
    IRON DEFICIENCY ANEMIA (IDA) Clinical Practice Guideline | March 2018 OBJECTIVE Alberta clinicians (specifically primary care and emergency department physicians) will be able to diagnose iron deficiency anemia (IDA), treat using oral and parenteral iron supplementation and provide ongoing management; will understand why red blood cell transfusion (RBC) may be harmful and is only occasionally required for the treatment of IDA. TARGET POPULATION Patients >5 years of age, hemodynamically stable, seen in emergency departments and primary care settings EXCLUSIONS Patients <5 years of age, all patients who are hemodynamically unstable, chronic kidney disease, rare genetic causes of and treatment of IDA, other types of iron deficiency, and the pre-latent stage of iron deficiency RECOMMENDATIONS ASSESSMENT INVESTIGATION FOR IDA Identify patients at risk for iron deficiency anemia Table 1: Possible Features, Signs and Symptoms of IDA ADULTS AND ADOLESCENTS Anticipated ongoing bleeding (e.g., menstruation, gastrointestinal) Head and neck manifestations including pallor (e.g., facial, conjunctival or palmar), blue sclerae, atrophic glossitis or loss of tongue papillae, angular cheilitis, alopecia Koilonychia (spoon nails) Restless leg syndrome Fatigue, shortness of breath, chest pain, lightheaded, syncope weakness, headache Irritability and/or depression Pica (craving/consumption of non-food substances e.g., dirt, clay, chalk) and pagophagia (ice craving) Decreased exercise tolerance Regular blood donors, particularly females donating more than twice a year and males donating more than three or four times a year SCHOOL-AGED CHILDREN (e.g., >5 to <18 years old) Tiredness, restlessness, irritability Pica and pagophagia Growth retardation Cognitive and intellectual impairment Signs of attention-deficit/hyperactivity disorder (ADHD) Breath-holding spells These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.
    [Show full text]
  • Local Anesthetic Agents Infiltration: Role of the Nurse
    Doug Ducey Joey Ridenour Governor Executive Director Arizona State Board of Nursing 1740 W Adams Street, Suite 2000 Phoenix. AZ 85007 Phone (602) 771-7800 Home Page: http://www.azbn.gov OPINION: INFILTRATION OF LOCAL An advisory opinion adopted by AZBN is an interpretation of what the law requires. While an ANESTHETIC AGENTS: THE ROLE OF THE advisory opinion is not law, it is more than a recommendation. In other words, an advisory opinion NURSE is an official opinion of AZBN regarding the practice of nursing as it relates to the functions of APPROVED DATE: 3/2015 nursing. Facility policies may restrict practice further in their setting and/or require additional REVISED DATE: 7/2018 expectations related to competency, validation, training, and supervision to assure the safety of their patient population and or decrease risk. ORIGINATING COMMITTEE: SCOPE OF PRACTICE COMMITTEE Within the Scope of Practice of X RN x LPN ADVISORY OPINION LOCAL ANESTHETIC AGENTS INFILTRATION: ROLE OF THE NURSE It is within the scope of practice of a registered nurse (RN) and a licensed practical nurse (LPN) to administer certain local anesthetic agents intradermal, subcutaneous, and submucosal for the purposes of analgesia and/or anesthesia prior to potentially painful procedures. Tumescent lidocaine infiltration for ambulatory procedures, such as but not limited to, the treatment of hyperhidrosis, ambulatory phlebectomy and laser facial resurfacings would be within the RN scope under the direction of an licensed independent practitioner (LIP) and when certain criteria is met within this advisory opinion. The licensed nurse must meet the general requirements and course of instruction listed in parts I and II.
    [Show full text]
  • Guideline: Assessment and Treatment of Pressure Ulcers in Adults & Children
    British Columbia Provincial Nursing Skin and Wound Committee Guideline: Assessment and Treatment of Pressure Ulcers in Adults & Children Developed by the BC Provincial Nursing Skin & Wound Committee in collaboration with Wound Clinicians from: / TITLE Guideline: Assessment and Treatment of Pressure Ulcers in Adults & Children1 Practice Level Nurses in accordance with health authority / agency policy. Care of clients 2 with pressure ulcers requires an interprofessional approach to provide comprehensive, evidence-based assessment and treatment. This clinical practice guideline focuses solely on the role of the nurse, as one member of the interprofessional team providing care to these clients. Background Researching existing data on pressure ulcer prevalence rates in Canada, Woodbury and Houghton (2004) found that mean pressure ulcer prevalence was 25.1% in acute care, 29.9% in non-acute care settings and 15.1% in community care with an overall mean prevalence rate of 26% across all settings.39 This prevalence data illustrates the significance of the problem and the need for consistent, evidence-based care. In pediatrics settings, a US multi-site national study found that the overall prevalence of skin breakdown was 18%, of which 4% was attributed to pressure ulcers.17 Pressure ulcers occur most commonly over bony prominences but can occur anywhere on the body when pressure, shearing force and friction are present and can lead to the death of underlying tissues. Heels and the sacrum are the two most common sites for pressure ulcers. Animal model studies have shown that a constant external pressure of 2 hours or longer can result in irreversible tissue damage.12 Populations at increased risk for pressure ulcers include those who have problems with peripheral circulation, are malnourished (overweight or underweight), have motor or sensory deficits, are incontinent, are immune compromised, have diabetes, renal failure, sepsis and/or cardiovascular problems or have had lower extremity surgery, especially hip replacements.
    [Show full text]
  • Anemia LECTURE in INTERNAL MEDICINE for IV COURSE
    Anemias in the mirror of the real clinical cases LECTURE IN INTERNAL MEDICINE FOR IV COURSE STUDENTS M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko, M. Brynza V.N. Karazin National University Medical School’ Internal Medicine Dept. Plan of the lecture • Definition • Epidemiology • Etiology & Mechanisms • Adaptation to anaemia • Classification • Clinical investigation • Diagnosis • Treatment • Prognosis • Prophylaxis • Abbreviations • Diagnostic guidelines http://anemiaofchronicdisease.com/wp-content/uploads/2012/08/anemia-of-chronic-disease1.jpg Definition Anemia is a disease and/or a clinical syndrome that consist in lowered ability of the blood to carry oxygen (hypoxia) due to decrease quantity and functional capacity and/or structural disturbances of red blood cells (RBCs) or decrease hemoglobin concentration or hematocrit in the blood A severe form of anemia, in which the hematocrit is below 10%, is called the hyperanemia WHO criteria is Hb < 13 g/dL in men and Hb < 12 g/dL in women (revised criteria for patient’s with malignancy Hb < 14 g/dL in men and Hb < 12g/dL in women) Epidemiology 1 https://www.k4health.org/sites/default/files/anemia-map_updated.png Epidemiology 2 http://img.medscape.com/fullsize/migrated/editorial/conferences/2006/4839/spivak.fig1.jpg Etiology & Mechanisms 1 (basic forms) Basic forms • Blood loss • Deficient erythropoiesis • Excessive hemolysis (RBC destruction) • Fluid overload (hypervolemia) http://www.merckmanuals.com/professional/hematology-and-oncology/approach-to-the-patient-with-anemia/etiology-of-anemia
    [Show full text]
  • Peripheral Edema with Hypoalbuminemia in a Nonhuman Primate Infected with Simian–Human Immunodeficiency Virus: a Case Report
    Journal of the American Association for Laboratory Animal Science Vol 47, No 1 Copyright 2008 January 2008 by the American Association for Laboratory Animal Science Pages 42–48 Case Report Peripheral Edema with Hypoalbuminemia in a Nonhuman Primate Infected with Simian–Human Immunodeficiency Virus: A Case Report Carol L Clarke,1,* Michael A Eckhaus,2 Patricia M Zerfas,2 and William R Elkins1 A rhesus macaque (Macaca mulatta) infected with simian-human immunodeficiency virus (SHIV) while undergoing AIDS research, required a comprehensive physical examination when it presented with slight peripheral edema, hypoalbuminemia, and proteinuria. Many of the clinical findings were consistent with nephrotic syndrome, which is an indication of glomerular disease, but the possibility of concurrent disease needed to be considered because lentiviral induced immune deficiency dis- ease manifests multiple clinical syndromes. The animal was euthanized when its condition deteriorated despite supportive care that included colloidal fluid therapy. Histopathology confirmed membranoproliferative glomerulonephritis, the result of immune complex deposition most likely due to chronic SHIV infection. Clinical symptoms associated with this histopathol- ogy in SHIV-infected macaques have not previously been described. Here we offer suggestions for the medical management of this condition, which entails inhibition of the renin–angiotensin–aldosterone system and diet modifications. Abbreviations: ACE, angiotensin-converting enzyme; SHIV, simian–human immunodeficiency
    [Show full text]
  • When Medications Fail to Control Seizures: a Case for Nonpharmacologic Options
    When Medications Fail To Control Seizures: A Case for Nonpharmacologic Options SELIM R. BENBADIS, MD Director, Comprehensive Epilepsy Program Associate Professor, Departments of Neurology and Neurosurgery University of South Florida, Tampa General Hospital Introduction ith a prevalence of 1% to 2%, epilepsy is a com- mon neurologic disorder.1 Not only is it one of the most common conditions seen in neurology practices, but it also affects young people in their prime working and reproductive years. While Wabout 70% of patients with seizures are controlled with medica- tions, approximately 30% are not.1,2 Thus, a standard general neu- rology practice inevitably includes a sizable number of patients with refractory seizures. A growing concern is that neurologists fail to identify and refer these patients, or do so too late. This is vividly illustrated by 2 facts: 1) the average delay from onset to correct diagnosis of psychogenic nonepileptic seizure (PNES) is 7 years3; 2) for patients who ultimately become seizure-free after surgery, the average delay from seizure onset to referral to an epilepsy surgery center is >15 years.4 There are basically 3 reasons why drugs may not work, which will all be discussed in this review: 1. The seizure-like episodes are not epileptic; 2. The medications chosen are not effective for the given epilepsy type; or 3. The epilepsy is medically intractable. The Misdiagnosis of Epilepsy The erroneous diagnosis of epilepsy is not rare and represents a significant problem.5,6 About one quarter of patients previously diagnosed with epilepsy are eventually found to be misdiagnosed, both in a referral epilepsy clinic and in epilepsy monitoring units.5,6 Many patients misdiagnosed as having epilepsy are even- tually shown to have PNES7 or syncope.8,9 Occasionally, other paroxysmal conditions can be misdiagnosed as epilepsy,including complicated migraines, paroxysmal movement disorders, and sleep disorders.
    [Show full text]
  • Osteonecrosis, Hip: [Print] - Emedicine Orthopedic Surgery Página 1 De 18
    Osteonecrosis, Hip: [Print] - eMedicine Orthopedic Surgery Página 1 de 18 emedicine.medscape.com eMedicine Specialties > Orthopedic Surgery > Hip Osteonecrosis, Hip Michael Levine, MD, Chairman, Department of Orthopedic Surgery, Western Pennsylvania Hospital Amar Rajadhyaksha, MD, Resident, Department of Orthopedic Surgery, New York Medical College; Michael Mont, MD, Associate Professor, Department of Orthopaedic Surgery, Johns Hopkins Medical Institution Updated: Mar 26, 2009 Introduction Osteonecrosis of the femoral head involves the hip joint, with osteocytes of the femoral head dying along with the bone marrow; resorption of the dead tissue by new but weaker osseous tissue can then lead to subchondral fracture and collapse. There are 2 forms of osteonecrosis: traumatic (the most common form) and atraumatic. Other terms to describe this disorder are avascular necrosis and ischemic necrosis to denote vascular etiology. The term aseptic necrosis also has been used to indicate that infection does not play a causative role. Alexander Munro first identified the condition in 1738. In the mid 1800s, Cruveilhier was the first to attribute the disorder to an aberration of circulation in the femoral head. Diagnosis of this disorder has increased because of improved technology and increased awareness. For excellent patient education resources, visit eMedicine's Breaks, Fractures, and Dislocations Center. Problem Osteonecrosis is now a commonly recognized disorder with significant morbidity. The end stage of the process is severe destruction of the femoral head with resultant degeneration of the hip joint. In many patients, even early identification and intervention do not alter the result. Unfortunately, patients who are affected with osteonecrosis are young, usually in the third to sixth decades of life.
    [Show full text]
  • Pitchaiah Mandava, M.D., Ph.D., MSEE (Page 1 of 6)
    Curriculum Vita — Pitchaiah Mandava, M.D., Ph.D., MSEE (Page 1 of 6) Pitchaiah Mandava, M.D., Ph.D., MSEE Associate Professor of Neurology Baylor College of Medicine Co-Director, Stroke Outcomes Laboratory Baylor College of Medicine Program Director, Vascular Neurology Fellowship Baylor College of Medicine CONTACT INFORMATION Pitchaiah Mandava, M.D., Ph.D., MSEE Baylor Neurology Baylor College of Medicine Medical Center, McNair Campus 7200 Cambridge St., 9th Floor, MS: BCM609 Houston, Texas 77030 Tel: 713-794-7201 Email: [email protected] CERTIFICATIONS American Board of Psychiatry and Neurology, Neurology American Board of Psychiatry and Neurology, Vascular Neurology United Council for Neurologic Subspecialties, Neurocritical Care EDUCATION M.D., The University of Texas, Medical Branch at Galveston, Texas Ph.D., The University of Texas, Dallas, Texas M.S.E.E., The University of Texas, Austin, Texas JOURNAL PUBLICATIONS 1. Tsivgoulis G, Katsanos AH, Eggers J, Larrue V, Thomassen L, Grotta JC, et al. Sonothrombolysis in patients with acute ischemic stroke with large vessel occlusion: An individual patient data meta-analysis. Stroke. 2021;:. PMID: 34428930. 2. Tsivgoulis G, Katsanos AH, Mandava P, Kohrmann M, Soinne L, Barreto AD, et al. Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis. J Hypertens. 2021;39(2):266-72. PMID: 32956103. 3. Katsanos AH, Alexandrov AV, Mandava P, Kohrmann M, Soinne L, Barreto AD, et al. Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis. Eur J Neurol. 2020;27(12):2453-62. PMID: 32697894. 4. Murthy SB, Cho SM, Gupta A, Shoamanesh A, Navi BB, Avadhani R, et al.
    [Show full text]
  • 6.Laser Discectomy
    Laser Discectomy: Overview, Periprocedural Care, Technique Page 1 of 8 Search No Results News & Perspective Drugs & Diseases CME & Education Laser Discectomy • Author: Jasvinder Chawla, MD, MBA; Chief Editor: Erik D Schraga, MD more... Updated: Aug 17, 2015 Overview Background Chronic low back pain is one of the major chronic debilitating conditions involving tremendous loss of money, work, and quality time. Lasers are used in different fields of medicine and confer unique advantages. In the treatment of lumbar disc disease, they are useful and advantageous. Laser discectomy is an outpatient procedure with one-step insertion of a needle into the disc space. Disc material is not removed; http://emedicine.medscape.com/article/1145539-overview 9/18/2016 Laser Discectomy: Overview, Periprocedural Care, Technique Page 2 of 8 instead, nucleus pulposus is burned by the laser. Laser discectomy is minimally invasive, cost-effective, and free of postoperative pain syndromes, and it is starting to be more widely used at various centers. The rapid acceptance of minimally invasive surgery in the United States has occurred largely without statistical proof of its superiority over traditional methods. All members of the healthcare field now see the need for valid outcome studies supporting the efficacy of new treatment techniques. Percutaneous laser disc decompression (PLDD) will gain wide acceptance only if it is demonstrated statistically to be a safe and effective alternative treatment for lumbar disc herniation. Epiduroscopic laser neural decompression is considered an effective treatment alternative for chronic refractory low back and/or lower extremity pain, including lumbar disc herniation, lumbar spinal stenosis, and failed back surgery syndrome that cannot be alleviated with existing noninvasive conservative treatment.[1] PLDD performed with computed tomographic (CT) and fluoroscopic guidance appears to be a safe and cost-effective treatment for herniated intervertebral discs and is being used with increasing frequency.
    [Show full text]